NCT07131085View on ClinicalTrials.gov

QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
MDSAML
Interventions
DRUG

Allogeneic TCR-enhanced γδ T cell(QH101)

dose escalation (3+3) : dose 1 (5×10\^8 enTCR γδ cells) , dose 2 (1.5×10\^9 enTCR γδ cells), dose 3 (3×10\^9 enTCR γδ cells)

DRUG

Fludarabine (FLU)

Intravenous fludarabine 20\~30 mg/m\^2/day on days -5, -4, and -3

DRUG

Cyclophosphamide (CTX)

Intravenous cyclophosphamide 300\~500 mg/m\^2/day on days -5, -4, and -3.

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV